Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kazia Therapeutics ( (KZIA) ) just unveiled an update.
On June 9, 2025, Kazia Therapeutics reported its unaudited half-year results for the period ending December 31, 2024, revealing a loss of $10.45 million, compared to $8.82 million the previous year. Despite financial challenges and a net current liability position, the company raised funds through an equity program and a line of credit, while also generating revenue from the sale of patents. The company’s ability to continue as a going concern depends on securing additional funding. Kazia’s lead drug, paxalisib, has shown promising results in clinical trials for glioblastoma, with several FDA designations enhancing its market potential.
The most recent analyst rating on (KZIA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is a pharmaceutical company engaged in research and development, focusing on commercializing its findings through licensing transactions. The company operates primarily in the pharmaceutical industry, with a key focus on developing treatments for brain cancers, including glioblastoma, using its lead program, paxalisib.
Average Trading Volume: 29,343
Technical Sentiment Signal: Sell
Current Market Cap: $6.32M
See more data about KZIA stock on TipRanks’ Stock Analysis page.